Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20130301
Title: MEK and the inhibitors: from bench to bedside.
Journal: Journal of hematology & oncology 20130101
Title: Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.
Journal: PloS one 20120101
Title: Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.
Journal: Science (New York, N.Y.) 20110415
Title: BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Journal: International journal of cancer 20101215
Title: Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
Journal: BMC cancer 20100101
Title: RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Journal: Cancer research 20090901
Title: Iverson C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47.
